Clinical Efficacy of Gadobutrol: Review of Over 25 Years of Use Exceeding 100 Million Administrations

Abstract

Background Gadobutrol has been administered more than 100 million times worldwide, since February 1998, that is, over the last 25 years. Numerous clinical studies in a broad range of indications document the long-term experience with gadobutrol. Objective The aim of this study was to provide a literature-based overview on gadobutrol's efficacy in 9 approved indications and use in children. Materials and Methods Efficacy results in patients of all age groups including sensitivity, specificity, accuracy, and positive/negative predictive values were identified by a systematic literature search on Embase until December 31, 2022. Nine approved indications were considered: central nervous system (CNS), magnetic resonance angiography (MRA), breast, heart, prostate, kidney, liver, musculoskeletal, whole body, and various indications in children. Results Sixty-five publications (10 phase III, 2 phase IV, 53 investigator-initiated studies) reported diagnostic efficacy results obtained from 7806 patients including 271 children, at 369 centers worldwide. Indication-specific sensitivity ranges were 59%–98% (CNS), 53%–100% (MRA), 80%–100% (breast), 64%–90% (heart), 64%–96% (prostate), 71–85 (kidney), 79%–100% (liver), 53%–98% (musculoskeletal), and 78%–100% (children). Indication-specific specificity ranges were 75%–100% (CNS), 64%–99% (MRA), 58%–98% (breast), and 47%–100% (heart). Conclusions The evaluated body of evidence, consisting of 65 studies with 7806 patients, including 271 children and 7535 adults, showed that gadobutrol is an efficacious magnetic resonance imaging contrast agent for all age groups in various approved indications throughout the whole body.